BioXcel Therapeutics, Inc.
BTAI
$2.03
$0.126.52%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -18.33% | -28.57% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -18.33% | -28.57% | |||
| Cost of Revenue | -89.72% | 664.29% | |||
| Gross Profit | 569.23% | -91.56% | |||
| SG&A Expenses | -4.06% | -1.58% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -11.52% | 55.57% | |||
| Operating Income | 11.47% | -56.97% | |||
| Income Before Tax | -61.10% | -164.50% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -61.10% | -164.50% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -61.10% | -164.50% | |||
| EBIT | 11.47% | -56.97% | |||
| EBITDA | 11.52% | -57.41% | |||
| EPS Basic | 11.00% | -63.03% | |||
| Normalized Basic EPS | 11.55% | -63.02% | |||
| EPS Diluted | 11.00% | -63.03% | |||
| Normalized Diluted EPS | 11.55% | -63.02% | |||
| Average Basic Shares Outstanding | 81.00% | 62.25% | |||
| Average Diluted Shares Outstanding | 81.00% | 62.25% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||